Get started
Author

Zhigang Weng

Identification of Src, Fyn, Lyn, PI3K and Abl SH3 domain ligands using phage display libraries.
1994 · R.J. Rickles, M.C. Botfield, et al. · The EMBO Journal · 254
PDF
Detection of Src homology 3-binding proteins, including paxillin, in normal and v-Src-transformed Balb/c 3T3 cells
1993 · Z. Weng, J.A. Taylor, et al. · Journal of Biological Chemistry · 215
Mice Lacking the Orphan G Protein-Coupled Receptor G2A Develop a Late-Onset Autoimmune Syndrome
2001 · Lu Q Le, Janusz H.S Kabarowski, et al. · Immunity · 214
PDF
MAP3K11/GDF15 axis is a critical driver of cancer cachexia
2015 · Lorena Lerner, Julie Tao, et al. · Journal of Cachexia Sarcopenia and Muscle · 199
PDF
GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
2010 · Ailin Bai, Kristan Meetze, et al. · Cancer Research · 151
A DNA damage and stress inducible G protein-coupled receptor blocks cells in G 2 /M
1998 · Zhigang Weng, Anne-Catherine Fluckiger, et al. · Proceedings of the National Academy of Sciences · 151
Structure-Function Analysis of SH3 Domains: SH3 Binding Specificity Altered by Single Amino Acid Substitutions
1995 · Zhigang Weng, Richard J. Rickles, et al. · Molecular and Cellular Biology · 125
Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface
2020 · Uddhav K. Shigdel, Seung-Joo Lee, et al. · Proceedings of the National Academy of Sciences · 81
PDF
Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
2014 · Kristan Meetze, Sylvie Vincent, et al. · Clinical Cancer Research · 58
Protection against Anoikis and Down-regulation of Cadherin Expression by a Regulatable β-Catenin Protein
2002 · Zhigang Weng, Mei Xin, et al. · Journal of Biological Chemistry · 35
A Functional Screen in Human Cells Identifies UBF2 as an RNA Polymerase II Transcription Factor That Enhances the β-Catenin Signaling Pathway
2003 · Dorre A. Grueneberg, Lourdes Pablo, et al. · Molecular and Cellular Biology · 27
First-in-human phase 1 dose-escalation study of AV-203, a monoclonal antibody against ERBB3, in patients with metastatic or advanced solid tumors.
2014 · John Sarantopoulos, Michael S. Gordon, et al. · Journal of Clinical Oncology · 18
Cyclosporin A analogues: recent advances
2003 · Tsvetelina Lazarova, Zhigang Weng · Expert Opinion on Therapeutic Patents · 6
PDF
Efficacy Analysis of Gefitinib +/- Ficlatuzumab in Serum Proteomic Based Subgroups of Patients with Previously Untreated Lung Adenocarcinoma
2014 · T.S.K. Mok, E. Tan, et al. · Annals of Oncology · 4
Abstract 4650: From bench to bedside: are cytokines still relevant biomarkers for staging cancer cachexia.
2013 · Antonio Vigano, Lorena Lerner, et al. · Cancer Research · 3
Abstract 3504: Plasma growth differentiating factor-15 (GDF-15) and other inflammatory markers are associated with weight loss and poor prognosis in cancer patients.
2013 · Lerner Lorena, Teresa Hayes, et al. · Cancer Research · 2
Abstract 2011: Feasibility of serum proteomic companion diagnostic (CDx) test development on the microflex LT platform
2015 · Nicholas Dupuis, Jamie Chang, et al. · Cancer Research · 1
Data from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
2023 · Kristan Meetze, Sylvie Vincent, et al.
Supplementary Materials and Methods, Figure Legends from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
2023 · Kristan Meetze, Sylvie Vincent, et al.
Supplementary Figures 1 - 4, Tables 1 - 2 from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
2023 · Kristan Meetze, Sylvie Vincent, et al.
PDF
Data from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
2023 · Kristan Meetze, Sylvie Vincent, et al.
Data from GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
2023 · Ailin Bai, Kristan Meetze, et al.
Supplementary Figures 1-4 from GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
2023 · Ailin Bai, Kristan Meetze, et al.
Supplementary Methods, Figure Legends 1-4 from GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
2023 · Ailin Bai, Kristan Meetze, et al.
PDF
Data from GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
2023 · Ailin Bai, Kristan Meetze, et al.
Works count: 32
Citation count: 1,544
H-index: 12
I10-index: 12
Year
Topic
Type